Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q2 2022 Earnings Conference Call August 3, 2022 8:30 AM ET Company Participants Ryan Crowe - Vice President, Investor Relations Leonard Schleifer - President, Chief Executive Officer George Yancopoulos - President, Chief Scientific Officer Marion McCourt - Executive Vice President, Head of Commercial Robert Landry - Executive Vice President, Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Evan Seigerman - BMO Capital Markets Tyler ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-344 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-34 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 13-3444607 ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Q4 2021 Results Conference Call February 4, 2022 8:30 AM ET Company Participants Mark Hudson - Director, IR Dr. Len Schleifer - Co-Founder, President, CEO & Executive Director Dr. George Yancopoulos - Co-Founder, President & Chief Scientific Officer Marion McCourt - EVP and Head of Commercial Bob Landry - EVP & CFO Conference Call Participants Evan Seigerman - BMO Carter Gould - Barclays Tyler Van Buren - Cowen Salveen Richter - Goldman Sachs Ronny Gal - Allianc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number: 0-19034 REGENERON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) New York 1 ...